Предиктивная роль амплификаций генов CCND1, FGFR1 и мутаций PIK3CA при гормонотерапии первично-метастатического рака молочной железы

Zwijsen RM, Buckle RS, Hijmans EM et al. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1 // Genes Dev. 1998;12:3488–98. https://doi:10.1101/gad.12.22.3488

Jirawatnotai S, Hu Y, Michowski W et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers // Nature. 2011;474:230–4. https://doi:10.1038/nature10155

Casimiro MC., Di Sante G, Crosariol M et al. Kinase-independent role of cyclin D1 in chromosomal instability and mammary tumorigenesis // Oncotarget. 2015;6:8525–38. https://doi:10.18632/oncotarget.3267

Gillett C, Fantl V, Smith R et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining // Cancer Res. 1994;54:1812–7.

Lundgren K, Brown M, Pineda S et al. Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study // Breast Cancer Res. 2012;14:R57. https://doi:10.1186/bcr3161

Roy PG, Pratt N, Purdie CA et al. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer // Int J Cancer. 2010;127:355–60. https://doi:10.1002/ijc.25034

Kenny FS, Hui R, Musgrove EA et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer // Clin Cancer Res. 1999;5:2069–76.

Bièche I, Olivi M, Noguès C et al. Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays // Br J Cancer. 2002;86:580–6. https://doi:10.1038/sj.bjc.6600109

Rudas M, Lehnert M, Huynh A et al. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy // Clin Cancer Res. 2008;14:1767–74. https://doi:10.1158/1078-0432.CCR-07-4122

Beca F, Pereira M, Cameselle-Teijeiro JF et al. Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer // BMC Cancer. 2015;15:285. https://doi:10.1186/s12885-015-1266-1

Ahlin C, Lundgren C, Embretsén-Varro E et al. High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers // Breast Cancer Res Treat. 2017;164:667–678. https://doi:10.1007/s10549-017-4294-5

Lundberg A, Lindström LS, Li J et al. The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours // Breast Cancer Res. 2019;21:34. https://doi:10.1186/s13058-019-1121-4

Stendahl M, Kronblad A, Rydén L et al. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients // Br J Cancer. 2004;90:1942–8. https://doi:10.1038/sj.bjc.6601831

Jirström K, Stendahl M, Rydén L et al. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification // Cancer Res. 2005;65:8009–16. https://doi:10.1158/0008-5472.CAN-05-0746

Ahnström M, Nordenskjöld B, Rutqvist LE et al. Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance // Breast Cancer Res Treat. 2005;91:145–51. https://doi:10.1007/s10549-004-6457-4

Brown LA, Johnson K, Leung S et al. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers // Breast Cancer Res Treat. 2010;121:347–54. https://doi:10.1007/s10549-009-0479-x

Theillet C, Adelaide J, Louason G et al. FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers // Genes Chromosomes Cancer. 1993; 7(4):219–26.

Turner N, Pearson A, Sharpe R et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer // Cancer Res. 2010;70:2085–94. https://doi:10.1158/0008-5472.CAN-09-3746

Tomiguchi M, Yamamoto Y, Yamamoto-Ibusuki M et al. Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer // Cancer Sci. 2016;107:491–8. https://doi:10.1111/cas.12897

Elbauomy Elsheikh S, Green AR, Lambros MB et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis // Breast Cancer Res. 2007;9:R23. https://doi:10.1186/bcr1665

Formisano L, Stauffer KM, Young CD et al. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer // Clin Cancer Res. 2017;23:6138–6150. https://doi:10.1158/1078-0432.CCR-17-1232

Jang M, Kim E, Choi Y et al. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma // Breast Cancer Res. 2012;14:R115. https://doi:10.1186/bcr3239

Shi YJ, Tsang JY, Ni YB et al. FGFR1 is an adverse outcome indicator for luminal A breast cancers // Oncotarget. 2016;7:5063–73. https://doi:10.18632/oncotarget.6563

Karlsson E, Waltersson MA, Bostner J et al. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1 // Genes Chromosomes Cancer. 2011;50:775–87. https://doi:10.1002/gcc.20900

Anderson EJ, Mollon LE, Dean JL et al. A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer // Int J Breast Cancer. 2020;2020:3759179. https://doi:10.1155/2020/3759179

Zardavas D, Te Marvelde L, Milne RL et al. Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data // J Clin Oncol. 2018;36(10):981–990. https://doi:10.1200/JCO.2017.74.8301

Mosele F, Stefanovska B, Lusque A et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer // Ann Oncol. 2020;31:377–386. https://doi:10.1016/j.annonc.2019.11.006

Perez EA, de Haas SL, Eiermann W et al. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. BMC // Cancer. 2019;19(1):517. https://doi:10.1186/s12885-019-5687-0

André F, Ciruelos EM, Juric D et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1 // Ann Oncol. 2021;32:208–217. https://doi:10.1016/j.annonc.2020.11.011

Barbareschi M, Buttitta F, Felicioni L et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas // Clin Cancer Res. 2007;13:6064–9. https://doi:10.1158/1078-0432.CCR-07-0266

Willis O, Choucair K, Alloghbi A et al. PIK3CA gene aberrancy and role in targeted therapy of solid malignancies // Cancer Gene Ther. 2020;27:634–644. https://doi:10.1038/s41417-020-0164-0

Yanus GA, Belyaeva AV, Ivantsov AO et al. Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients // Med Oncol. 2013;30:686. https://doi:10.1007/s12032-013-0686-5

Han S, Park K, Bae BN et al. Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer // Oncol Rep. 2003;10:141–4.

Bostner J, Ahnström Waltersson M, Fornander T et al. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer // Oncogene. 2007;26:6997–7005. https://doi:10.1038/sj.onc.1210506

Keilty D, Buchanan M, Ntapolias K et al. RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial // PLoS One. 2013;8:e81740. https://doi:10.1371/journal.pone.0081740

Giltnane JM, Hutchinson KE, Stricker TP et al. Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance // Sci Transl Med. 2017;9(402). https://doi:10.1126/scitranslmed.aai7993

Drago JZ, Formisano L, Juric D et al. FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR(+)) Breast Cancer // Clin Cancer Res. 2019;25:6443–6451. https://doi:10.1158/1078-0432.CCR-19-0138

Miller TW, Balko JM, Arteaga CL Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer // J Clin Oncol. 2011;29:4452–61. https://doi:10.1200/JCO.2010.34.4879

Ramirez-Ardila DE, Helmijr JC, Look MP et al. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen // Breast Cancer Res Treat. 2013;139:39–49. https://doi:10.1007/s10549-013-2529-7

Ellis MJ, Lin L, Crowder R et al. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer // Breast Cancer Res Treat. 2010;119:379–90. https://doi:10.1007/s10549-009-0575-y

Beelen K, Opdam M, Severson TM et al. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients // Breast Cancer Res. 2014;16(1):R13. https://doi:10.1186/bcr3606

Sabine VS, Crozier C, Brookes CL et al. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study // J Clin Oncol. 2014;32:2951-8. https://doi:10.1200/JCO.2013.53.8272

Loi S, Haibe-Kains B, Majjaj S et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer // Proc Natl Acad Sci USA. 2010;107:10208–13. https://doi:10.1073/pnas.0907011107